Xeris Biopharma Holdings, Inc. (XERS) Dividend History

Company News

• Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates

  Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: VRCA
• Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?

  MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  Zacks Investment Research

  Featured Companies: MDWD
• Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

  Xeris Biopharma's financial success in compounding healthcare investing may be uncertain due to competition and FDA approval risks. Read more on XERS stock here.

  Seeking Alpha
• Why Xeris (XERS) Might Surprise This Earnings Season

  Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  Zacks Investment Research
• Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza

  Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.

  Zacks Investment Research

  Featured Companies: ADMA AMGN PBYI